A 52-Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder.

Trial Profile

A 52-Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Autistic disorder
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb; Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 27 May 2010 Efficacy results reported at American Psychiatric Association (APA) meeting.
    • 29 Sep 2009 Actual patient number (330) added as reported by ClinicalTrials.gov.
    • 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top